Alcami, a contract development and manufacturing organisation (CDMO), announced on Tuesday that it has completed Phase II of its cGMP biostorage facility situated in Amherst, New Hampshire.
The company's 104,000 square feet area is now completely operational and supports various cGMP storage requirements. The whole site covers a total area of 160,000 square feet.
The company is planning to complete phase III in the first quarter of 2023 and will add an additional 56,000 square feet of new capacity.
Arcturus Therapeutics and Thermo Fisher enter strategic collaboration on ARCT-032 development
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
Neurocrine Biosciences initiates crinecerfont Phase 2 study in young children with classic CAH
Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC
Ipsen to acquire Memo Therapeutics to expand rare disease portfolio
Eurobio Scientific completes acquisition of CareDx's transplant lab products business
Aspen Neuroscience completes Cohort 3 and 4 dosing in Parkinson's disease trial
Biohaven completes enrolment in opakalim RISE 3 epilepsy study